Dianthus Therapeutics, Inc.
DNTH
Kedudukan dalam Saham
#4061
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Harga Saham
$71.45
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$4.00B
Perubahan (1 hari)
-4.13%
Perubahan (1 tahun)
100.42%
Negara
US
Perdagangan Dianthus Therapeutics, Inc. (DNTH)
Kategori
Healthcare
EPS untuk Dianthus Therapeutics, Inc. (DNTH)
EPS setakat June 2026 TTM: $-0.13
Menurut laporan kewangan terkini dan harga saham Dianthus Therapeutics, Inc., EPS semasa syarikat (TTM) adalah $-0.13. Pada akhir tahun 2023, syarikat mempunyai EPS sebanyak $-8.45 peningkatan berbanding EPS tahun 2022 iaitu $-7.60.
Sejarah EPS untuk Dianthus Therapeutics, Inc. dari 2016 hingga 2026
EPS pada akhir setiap tahun
| Tahun | EPS | Ubah |
|---|---|---|
| 2026 (TTM) | $-0.13 | -94.90% |
| 2024 | $-2.55 | -69.82% |
| 2023 | $-8.45 | 11.18% |
| 2022 | $-7.60 | 98.95% |
| 2021 | $-3.82 | -86.01% |
| 2020 | $-27.30 | -17.72% |
| 2019 | $-33.18 | 20.13% |
| 2018 | $-27.62 | 72.09% |
| 2017 | $-16.05 | 275.88% |
| 2016 | $-4.27 | 0.00% |
EPS untuk syarikat atau pesaing yang serupa
| Syarikat | EPS | Perbezaan EPS | Negara |
|---|---|---|---|
| $17.32 | -13,423.08% |
US
|
|
| $-7.98 | 6,038.46% |
US
|
|
| $-5.29 | 3,969.23% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -21,438.46% |
NL
|
